Which is better, CRMD or SANOFICONR.BO?

On the Buffett-Fit framework, Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) currently grades higher than CRMD — 78/100 (B grade) vs 63/100 (C). That said, "better" depends on which framework you trust — CRMD wins on none; SANOFICONR.BO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy CRMD or SANOFICONR.BO?

This page is an educational comparison, not investment advice. Both CRMD and SANOFICONR.BO are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is CRMD better than SANOFICONR.BO for value investing?

On the Buffett-style value-investing framework, SANOFICONR.BO currently grades higher — 78/100 vs 63/100, a 15-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between CRMD and SANOFICONR.BO on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). CRMD currently scores 63/100 (C grade); SANOFICONR.BO scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, CRMD or SANOFICONR.BO?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. CRMD and SANOFICONR.BO are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, CRMD or SANOFICONR.BO?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are CRMD and SANOFICONR.BO both Healthcare stocks?

Yes — both CorMedix Inc. (CRMD) and Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this CRMD vs SANOFICONR.BO comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

CorMedix

CRMD$583.68MHealthcare Market cap, Sector

Sanofi Consumer Healthcare India Limited

SANOFICONR.BO$104.05BHealthcare Market cap, Sector

Overall winner

Sanofi Consumer Healthcare India Limited

CRMD 07 SANOFICONR.BO

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

CRMD0wins

7winsSANOFICONR.BO

Warren Buffett

63C

B78

Benjamin Graham

38F

A89

Philip Fisher

64C

B83

Peter Lynch

64C

B77

Joel Greenblatt

48D

A91

Charlie Munger

67C

A86

Terry Smith

71B

A85

Side-by-side metrics

Metric	CRMD	SANOFICONR.BO
Market cap	$583.68M	$104.05B Winner
P/E (TTM)	Winner: 3.3x	44.0x
EV/EBIT	Winner: 3.7x	31.7x
ROIC (TTM)	27.59%	59.15% Winner
Gross margin	Winner: 85.83%	68.13%
Net margin	Winner: 45.25%	27.35%
Revenue CAGR 5y	Winner: 5.36%	27.01%
EPS CAGR 5y	-	20.67%
Debt / Equity	0.3x	0.1x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CRMD leads on

Revenue CAGR 5y5.36%vs 27.01%+95%
P/E (TTM)3.3xvs 44.0x+92%
EV/EBIT3.7xvs 31.7x+88%
Net margin45.25%vs 27.35%+40%

SANOFICONR.BO leads on

Market cap$104.05Bvs $583.68M+99%
Debt / Equity0.1xvs 0.3x+81%
ROIC (TTM)59.15%vs 27.59%+53%

More like CRMD

CRMD vs 1681.HK CRMD vs SANOFICONR.NS CRMD vs PME.AX CRMD vs CAMX.ST

More like SANOFICONR.BO

SANOFICONR.BO vs 1681.HK SANOFICONR.BO vs SANOFICONR.NS SANOFICONR.BO vs PME.AX SANOFICONR.BO vs CAMX.ST

Read the full Buffett-Brain analysis for CRMD Read the full Buffett-Brain analysis for SANOFICONR.BO

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Side-by-side metrics

Metric	CRMD	SANOFICONR.BO
Market cap	$583.68M	$104.05B Winner
P/E (TTM)	Winner: 3.3x	44.0x
EV/EBIT	Winner: 3.7x	31.7x
ROIC (TTM)	27.59%	59.15% Winner
Gross margin	Winner: 85.83%	68.13%
Net margin	Winner: 45.25%	27.35%
Revenue CAGR 5y	Winner: 5.36%	27.01%
EPS CAGR 5y	-	20.67%
Debt / Equity	0.3x	0.1x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CRMD leads on

Revenue CAGR 5y5.36%vs 27.01%+95%
P/E (TTM)3.3xvs 44.0x+92%
EV/EBIT3.7xvs 31.7x+88%
Net margin45.25%vs 27.35%+40%

SANOFICONR.BO leads on

Market cap$104.05Bvs $583.68M+99%
Debt / Equity0.1xvs 0.3x+81%
ROIC (TTM)59.15%vs 27.59%+53%